Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05494424
Other study ID # Traincovid
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 8, 2023
Est. completion date January 2029

Study information

Verified date September 2023
Source Lovisenberg Diakonale Hospital
Contact Head of Research at Lovisenberg Hospital
Phone (+47) 95033144
Email anners.lerdal@lds.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-COVID-19 condition is frequently comprised of persistent cognitive sequela, including deficits in attention and executive functions (EFs). Goal Management Training (GMT) is a cognitive rehabilitation (CR) intervention for improving attention and EFs that has received empirical support in studies of other patient groups. The present study aims to determine the efficacy of GMT for improving everyday attention and EFs in adults who experience persistent cognitive deficits after COVID-19. The study is a randomized controlled trial (RCT), comparing the efficacy of GMT to a wait list control condition (WL), for improving persistent cognitive sequela in post-COVID-19 condition. The study aims to recruit 240 participants aged 18 to 65 years with a history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) and perceived attentional and EF difficulties in daily life that have lasted for at least two months and that cannot be explained by an alternative diagnosis. Participants will be randomized to either group-based GMT (n = 120) or WL (n = 120). GMT will be internet-delivered to groups of six participants in six two-hour sessions delivered weekly (five weeks). The primary outcome will be the Metacognition Index of the Behavior Rating Inventory of Executive Function - Adult Version, a self-report measure assessing everyday EF difficulties, at six months post-treatment. Secondary outcomes include performance-based neurocognitive measures and rating scales of cognition, emotional health, quality of life, and fatigue. Secondary aims include to explore to what extent potential early change predicts outcome, and to examine what characterize those who profit from GMT, in addition to describe the neurocognitive and emotional health in a Covid-19 sample. The investigators will also examine potential effects of GMT at 2- and 5-year follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date January 2029
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) - perceived cognitive difficulties (attention, memory, EF) affecting everyday functioning that have lasted for at least two months and that cannot be explained by an alternative diagnosis - age between 18-65 years Exclusion Criteria: - ongoing alcohol- or substance abuse, premorbid insult and/or comorbid neurological disease, severe neurocognitive problems interfering with the capacity to participate, sensory disorders biasing cognitive assessment, psychotic disorders, lack of proficiency in Norwegian, and being previously enrolled in a GMT trial.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Goal Management Training (GMT)
Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.

Locations

Country Name City State
Norway Lovisenberg Diaconal Hospital Oslo

Sponsors (6)

Lead Sponsor Collaborator
Lovisenberg Diakonale Hospital Icahn School of Medicine at Mount Sinai, Oslo University Hospital, UiT The Arctic University of Norway, University of Oslo, University of Toronto

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Metacognition Index from the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Self-report measure of daily life executive function (metacognition). Range:70-210. Higher score indicate greater executive dysfunction. Change from baseline up to 6 months
Secondary The Behaviour regulation Index from Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Self-report measure of daily life executive function (behaviour regulation). Range: 70-210. Higher score indicate greater executive dysfunction. Change from baseline up to 6 months
Secondary Cambridge Neuropsychological Test Automated Battery (CANTAB), subtests: the Stop Signal Task, Spatial Working Memory, Intra-Extra Dimensional Set Shift and Rapid Visual Information Processing Performance-based neurocognitive test battery Change from baseline up to 6 months
Secondary The Hospital Anxiety and Depression Scale Self-report measure of symptoms of anxiety and depression. The maximum score is 21 for depression and 21 for anxiety, range 0-21 on each scale. A higher score = more symptoms. Change from baseline up to 6 months
Secondary The Generalized Self-Efficacy Scale Self-report measure of self-efficacy. Range:10-40. Higher score indicate higher self-efficacy. Change from baseline up to 6 months
Secondary Fatigue Severity Scale Self-report measure of fatigue. 7 items. Range 7-49. Higher score indicate more fatigue. Change from baseline up to 6 months
Secondary The Perceived Deficits Questionnaire Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 80, with a higher score indicating greater perceived cognitive impairment. Change from baseline up to 6 months
Secondary Everyday Memory Questionnaire Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 52, with a higher score indicating greater perceived cognitive impairment. Change from baseline up to 6 months
Secondary RAND 12-Item Health Survey (RAND-12) Self-report measure of quality of life. Range 0-10; a high score defines a more favorable health state. Change from baseline up to 6 months
Secondary EuroQol five-dimension scale questionnaire (EQ-5D) Self-report measure of quality of life. The range of the EQ-5D index scores is 0 to 1 (1 indicates the best health state), but negative scores as low as-0.59 are possible for health states deemed to be worse than death. Change from baseline up to 6 months
Secondary DUKE-UNC Functional Social Support Questionnaire (FSSQ) Self-report measure of social support. 8 items. The total score range from 8 to 40. Higher score indicates more social support. Change from baseline up to 6 months
Secondary DePaul Symptom Questionnaire short version Self-report measure of fatigue symptoms. 14 items. The total score range from 0 to 56 for both frequency and severity for each item. Change from baseline up to 6 months
Secondary The Resilience Scale for Adults Self-report measure of resilience. 33 items. The total score range from 33 to 165 Change from baseline up to 6 months
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
Recruiting NCT05200832 - Impact of Long COVID-19 on the Health and Quality of Life of Military Personnel (Active or Retired) and Their Families